Extrahepatic manifestations of HCV: the role of direct acting antivirals

References

• Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482–496.
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(5 Suppl 1):S21–S29.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9(3):383–398, vi.
   PubMedGoogle Scholar
• Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303–1310.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53(4):1100–1108.
   PubMed Web of Science ®Google Scholar
• Ragab G, Hussein MA. Vasculitic syndromes in hepatitis C virus: a review. J Adv Res. 2017;8(2):99–111.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1):3–14.
   PubMed Web of Science ®Google Scholar
• Palazzi C, Buskila D, D’Angelo S, et al. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev. 2012;11(9):659–663.
   PubMed Web of Science ®Google Scholar
• Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25(1):10–18.
   PubMed Web of Science ®Google Scholar
• Ko HM, Hernandez-Prera JC, Zhu H, et al. Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol. 2012;740138:2012.
   Google Scholar
• Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56(2):455–463.
   PubMed Web of Science ®Google Scholar
• Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25.
   PubMed Web of Science ®Google Scholar
• Terrier B, Cacoub P. Renal involvement in HCV-related vasculitis. Clin Res Hepatol Gastroenterol. 2013;37(4):334–339.
   PubMed Web of Science ®Google Scholar
• Latt N, Alachkar N, Gurakar A. Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol (N Y). 2012;8(7):434–445.
   PubMedGoogle Scholar
• Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum. 1999;42(10):2204–2212.
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469–477.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64(11):1824–1833.
   PubMed Web of Science ®Google Scholar
• Gotte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol. 2016;13(6):338–351.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Saadoun D. Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol. 2008;35(1–2):30–39.
   PubMed Web of Science ®Google Scholar
• Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994;106(5):1291–1300.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Sansonno D, Piccoli C, et al. The cryoglobulins: an overview. Eur J Clin Invest. 2001;31(7):628–638.
   PubMed Web of Science ®Google Scholar
• Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum. 1998;28(2):107–113.
   PubMed Web of Science ®Google Scholar
• Palazzi C, Olivieri I, Cacciatore P, et al. Difficulties in the differential diagnosis between primitive rheumatic diseases and hepatitis C virus-related disorders. Clin Exp Rheumatol. 2005;23(1):2–6.
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Yeshurun D, Rosner I. Management of hepatitis C virus-related arthritis. BioDrugs. 2001;15(9):573–584.
   PubMed Web of Science ®Google Scholar
• D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int. 1998;54(2):650–671.
   PubMed Web of Science ®Google Scholar
• Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens. 2005;14(4):396–403.
   PubMed Web of Science ®Google Scholar
• Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47(2):618–623.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–1832.
   PubMed Web of Science ®Google Scholar
• Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med. 2005;165(1):101–105.
   PubMedGoogle Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–374.
   PubMed Web of Science ®Google Scholar
• Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood. 1994;84(9):3047–3053.
   PubMed Web of Science ®Google Scholar
• Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55(1):4–13.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Garcia-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125(6):1723–1732.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Kusano A, Sugumar A, et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95(9):745–752.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2078–2085.
   PubMed Web of Science ®Google Scholar
• Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131(6):1879–1886.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451–458.
   PubMed Web of Science ®Google Scholar
• Martyak LA, Yeganeh M, Saab S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin’s lymphoma. Clin Gastroenterol Hepatol. 2009;7(8):900–905.
   PubMed Web of Science ®Google Scholar
• Moehlen M, Abbas A, Balart LA. Hepatitis B and C are associated with non-Hodgkin lymphoma: cross-sectional study of the National Inpatient Sample database. Hepatology. 2012;56:631a–632a.
   Google Scholar
• Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin’s lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016;8(2):107–116.
   PubMedGoogle Scholar
• Libra M, Polesel J, Russo AE, et al. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? Int J Oncol. 2010;36(6):1331–1340.
   PubMed Web of Science ®Google Scholar
• Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet. Oncol. 2009;10(4):321–322.
   PubMed Web of Science ®Google Scholar
• Wang RY, Bare P, De Giorgi V, et al. Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system. Hepatology. 2016;64(6):1900–1910.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol. 2012;2012:980942.
   PubMedGoogle Scholar
• Rebora A. Skin diseases associated with hepatitis C virus: facts and controversies. Clin Dermatol. 2010;28(5):489–496.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Garcia-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39(4):620–627.
   PubMed Web of Science ®Google Scholar
• Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta. 2009;1790(7):663–670.
   PubMed Web of Science ®Google Scholar
• Tanei R, Watanabe K, Nishiyama S. Clinical and histopathologic analysis of the relationship between lichen planus and chronic hepatitis C. J Dermatol. 1995;22(5):316–323.
   PubMedGoogle Scholar
• Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis. 2010;16(7):601–612.
   PubMed Web of Science ®Google Scholar
• Pilli M, Penna A, Zerbini A, et al. Oral lichen planus pathogenesis: a role for the HCV-specific cellular immune response. Hepatology. 2002;36(6):1446–1452.
   PubMed Web of Science ®Google Scholar
• Carrozzo M, Scally K. Oral manifestations of hepatitis C virus infection. World J Gastroenterol. 2014;20(24):7534–7543.
   PubMed Web of Science ®Google Scholar
• Petrides AS, Vogt C, Schulze-Berge D, et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology. 1994;19(3):616–627.
   PubMed Web of Science ®Google Scholar
• White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–844.
   PubMed Web of Science ®Google Scholar
• Hammerstad SS, Grock SF, Lee HJ, et al. Diabetes and hepatitis C: a two-way association. Front Endocrinol (Lausanne). 2015;6:134.
   PubMed Web of Science ®Google Scholar
• Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003;18(6):549–558.
   PubMed Web of Science ®Google Scholar
• Chen LK, Chou YC, Tsai ST, et al. Hepatitis C virus infection-related type 1 diabetes mellitus. Diabet Med. 2005;22(3):340–343.
   PubMed Web of Science ®Google Scholar
• Masuda H, Atsumi T, Fujisaku A, et al. Acute onset of type 1 diabetes accompanied by acute hepatitis C: the potential role of proinflammatory cytokine in the pathogenesis of autoimmune diabetes. Diabetes Res Clin Pract. 2007;75(3):357–361.
   PubMed Web of Science ®Google Scholar
• Yan FM, Chen AS, Hao F, et al. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol. 2000;6(6):805–811.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473–1482.
   PubMed Web of Science ®Google Scholar
• Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15(4):575–583e571.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153(1):49-52.
   Web of Science ®Google Scholar
• Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527–2532.
   PubMed Web of Science ®Google Scholar
• Alric L, Besson C, Lapidus N, et al. Antiviral treatment of HCV-infected patients with B-cell non-Hodgkin lymphoma: ANRS HC-13 lympho-C study. PloS One. 2016;11(10):e0162965.
   PubMed Web of Science ®Google Scholar
• Rossotti R, Travi G, Pazzi A, et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol. 2015;62(1):234–237.
   PubMed Web of Science ®Google Scholar
• Sultanik P, Klotz C, Brault P, et al. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125(15):2446–2447.
   PubMed Web of Science ®Google Scholar
• Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015;35(10):2222–2227.
   PubMed Web of Science ®Google Scholar
• Pavone P, Tieghi T, d’Ettorre G, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22(5):462 e461–e463.
   Web of Science ®Google Scholar
• Nagao Y, Kimura K, Kawahigashi Y, et al. Successful treatment of hepatitis C virus-associated oral lichen planus by interferon-free therapy with direct-acting antivirals. Clin Transl Gastroenterol. 2016;7(7):e179.
   PubMed Web of Science ®Google Scholar
• Hatch MM, Nawas Z, Kollipara R, et al. Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients? J Eur Acad Dermatol Venereology: JEADV. 2016;31(4):e194.
   PubMed Web of Science ®Google Scholar
• Tong Y, Song YK, Tyring S. Resolution of porphyria cutanea tarda in patients with hepatitis C following ledipasvir-sofosbuvir combination therapy. JAMA Dermatol. 2016;152(12):1393–1395.
   PubMed Web of Science ®Google Scholar
• Combalia A, To-Figueras J, Laguno M, et al. Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. Br J Dermatol. 2017. doi: 10.1111/bjd.15502.
   PubMedGoogle Scholar
• Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035–1045.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61(4):1145–1153.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Craxi A. Why do I treat my patients with mild hepatitis C? Liver Int. 2016;36(Suppl 1):7–12.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis. 2008;67(3):283–287.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777–1782.
   PubMed Web of Science ®Google Scholar
• Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408–417.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Garrido M, Pol S, et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152(8):2052–2062e2052.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523–541.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Vautier M, Desbois AC, et al. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: from interferon-based to direct-acting antivirals era. Liver Int. 2017;00:1-9. https://doi.org/10.1111/liv.13465.
   Google Scholar
• Cacoub P, Commarmond C, Sadoun D, et al. Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents. Rheum Dis Clin North Am. 2017;43(1):123–132.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, −2, and −3 clinical trials. Hepatology. 2015;61(6):1798–1808.
   PubMed Web of Science ®Google Scholar
• Tasleem S, Sood GK. Hepatitis C associated B-cell non-Hodgkin lymphoma: clinical features and the role of antiviral therapy. J Clin Transl Hepatol. 2015;3(2):134–139.
   PubMedGoogle Scholar
• Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404–1410.
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Arcaini L, Hansmann ML, et al. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169–177.
   PubMed Web of Science ®Google Scholar
• La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49(4):557–563.
   PubMed Web of Science ®Google Scholar
• De Clerck F, Geerts A, Brochez L, et al. Successful treatment of HCV-associated B-cell non-Hodgkin lymphomas with direct-acting antiviral agents. J Clin Gastroenterol. 2016;50(5):438.
   PubMed Web of Science ®Google Scholar
• Sise ME, Wisocky J, Rosales IA, et al. Lupus-like immune complex-mediated glomerulonephritis in patients with hepatitis C virus infection treated with oral, interferon-free, direct-acting antiviral therapy. Kidney Int Rep. 2016;1(3):135–143.
   PubMed Web of Science ®Google Scholar
• Artemova M, Abdurakhmanov D, Ignatova T, et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65(5):1770–1771.
   PubMed Web of Science ®Google Scholar
• Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology. 2016;55(11):2084–2085.
   PubMed Web of Science ®Google Scholar
• Nagao Y, Kawaguchi T, Ide T, et al. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med. 2005;15(2):237–241.
   PubMed Web of Science ®Google Scholar
• Nagao Y, Sata M, Ide T, et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest. 1996;26(12):1171–1174.
   PubMed Web of Science ®Google Scholar
• Misaka K, Kishimoto T, Kawahigashi Y, et al. Use of direct-acting antivirals for the treatment of hepatitis C virus-associated oral lichen planus: a case report. Case Rep Gastroenterol. 2016;10(3):617–622.
   PubMedGoogle Scholar
• Wiznia LE, Laird ME, Franks AG Jr. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era. J Eur Acad Dermatol Venereology: JEADV. 2017. doi: 10.1111/jdv.14186.
   PubMed Web of Science ®Google Scholar
• Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48(2):105–111.
   PubMedGoogle Scholar